Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society

Kardiol Pol. 2017;75(3):286-293. doi: 10.5603/KP.2017.0056.
No abstract available

MeSH terms

  • Aminobutyrates / therapeutic use*
  • Angiotensin Receptor Antagonists / therapeutic use*
  • Biphenyl Compounds
  • Cardiology / standards
  • Drug Combinations
  • Heart Failure / drug therapy*
  • Humans
  • Patient Care Management
  • Poland
  • Recovery of Function
  • Societies, Medical / standards
  • Stroke Volume
  • Tetrazoles / therapeutic use*
  • Treatment Outcome
  • Valsartan

Substances

  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • Valsartan
  • sacubitril and valsartan sodium hydrate drug combination